HARVARD BIOSCIENCE INC HBIO
Nasdaq · XNAS · stock · Laboratory Analytical Instruments
Chart by TradingView
4/9
Piotroski F — financial health
-10.45
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $86.5M | -$56.7M | $49.9M | $5.5M | $13.7M |
| 2025 | — | -$12.4M | — | — | $14.1M |
| 2024 | $94.1M | -$12.4M | $54.8M | -$1.2M | $63.3M |
| 2023 | $112.2M | -$3.4M | $66.1M | $12.2M | $73.1M |
| 2022 | $113.3M | -$9.5M | $60.8M | -$438,000 | $72.2M |
| 2021 | $118.9M | -$288,000 | $67.7M | $67,000 | $83.4M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Eade Katherine A. | director | 2026-06-09 | Grant | 16,556 | — |
| Snider William | director | 2026-06-09 | Grant | 16,556 | — |
| DENELSKY STEPHEN J | director | 2026-06-09 | Grant | 16,556 | — |
| Gagnon Robert E. | director | 2026-06-09 | Grant | 16,556 | — |
| Benson Seth Benjamin | director | 2026-06-09 | Grant | 16,556 | — |
| Frost Mark T | Chief Financial Officer | 2026-03-20 | Grant | 30,000 | — |
| Duke John D | Chief Executive Officer | 2026-03-20 | Grant | 75,000 | — |
| Snider William | director | 2026-03-17 | Buy | 8,475 | $4.85 |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -10.45 (distress)
- Working capital / assets 0.328
- Retained earnings / assets -2.681
- EBIT / assets -0.607
- Equity / liabilities 0.207
Source: SEC EDGAR filings · CIK 0001123494 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.